Article(id=1329837548194607972, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329837471875051704, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2024.03.017, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1695398400000, receivedDateStr=2023-09-23, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794987578675, onlineDateStr=2026-11-18, pubDate=1710000000000, pubDateStr=2024-03-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794987578675, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794987578675, creator=13701087609, updateTime=1794987578675, updator=13701087609, issue=Issue{id=1329837471875051704, tenantId=1146029695717560320, journalId=1319690329412173987, year='2024', volume='45', issue='3', pageStart='233', pageEnd='344', issueExtLink='null', onlineDate='null', pubDate='1710000000000', pubDateStr='2024-03-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794987560480, creator='13701087609', updateTime=1794988245359, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329840345090732938, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329837471875051704, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329840345090732939, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329837471875051704, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=338, endPage=340, ext={EN=ArticleExt(id=1329837548366574437, articleId=1329837548194607972, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Oral selective estrogen receptor depressant, the new anti-breast cancer drug elacestrant, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Selective estrogen receptor degrader (SERD) is commonly used in the endocrine therapy of estrogen receptor (ER) positive advanced breast cancer. Elacestrant is a novel oral SERD that is for the treatment of advanced breast cancer with ER-positive and human epidermal growth factor receptor (HER)2-negative. It is more effective than other endocrine therapies and can significantly improve the median progression free survival of patients, and is also effective for breast cancer patients with ER gene α mutations. The launch of elacestrant will provide a more effective treatment option for patients with ER-positive, HER2-negative advanced breast cancer.

, authors=Fanxin ZENG1, Kesi WANG2, authorsList=Fanxin ZENG, Kesi WANG, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329837548576289638, articleId=1329837548194607972, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=口服选择性雌激素受体降解剂抗乳腺癌新药艾拉司群, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

选择性雌激素受体降解剂(selective estrogen receptor degrader,SERD)是雌激素受体(estrogen receptor,ER)阳性的晚期乳腺癌(breast cancer)内分泌治疗的常用药物。艾拉司群(elacestrant)是治疗晚期乳腺癌ER阳性,人表皮细胞生长因子受体(human epidermal growth factor receptor,HER)2阴性的新型口服SERD,疗效优于其他内分泌治疗,可显著改善患者中位无进展生存期,且对于ER基因α突变的乳腺癌患者有效。艾拉司群的上市将为ER阳性、HER2阴性的晚期乳腺癌患者提供更有效的治疗药物选择。

, authors=曾凡新1, 王柯厶2, authorsList=曾凡新, 王柯厶, authorCompany=null, correspAuthors=null, authorNote=

曾凡新,教授,研究方向:新药研究开发。

, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=kFMpSFfSeAhuarlLGc5CyQ==, magXml=Ikqf1ehQNHNJ9UUthDE+bw==, pdfUrl=null, pdf=RQAmk9PwwV5oz5j8daPHVA==, pdfFileSize=1550671, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=z+U8Ecsq+2o7LfztzZ/Axg==, mapNumber=null, fund=null)}, authors=[Author(id=1329837548941194094, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329837549012497264, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, authorId=1329837548941194094, language=EN, stringName=Fanxin ZENG, firstName=Fanxin, middleName=null, lastName=ZENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.School of Smart Healthcare Industry, Chongqing City Management College, Chongqing 401331, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837549117354865, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, authorId=1329837548941194094, language=CN, stringName=曾凡新, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.重庆城市管理职业学院智慧康养学院,重庆 401331, bio={"content":"

曾凡新,教授,研究方向:新药研究开发。

"}, bioImg=null, bioContent=

曾凡新,教授,研究方向:新药研究开发。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837548765033319, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, xref=1., ext=[AuthorCompanyExt(id=1329837548773421928, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, companyId=1329837548765033319, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of Smart Healthcare Industry, Chongqing City Management College, Chongqing 401331, China), AuthorCompanyExt(id=1329837548781810537, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, companyId=1329837548765033319, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.重庆城市管理职业学院智慧康养学院,重庆 401331)])]), Author(id=1329837549205435251, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329837549335458677, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, authorId=1329837549205435251, language=EN, stringName=Kesi WANG, firstName=Kesi, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.School of Pharmacy, Chongqing Medical and Pharmaceutical College, Chongqing 401331, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837549402567542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, authorId=1329837549205435251, language=CN, stringName=王柯厶, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.重庆医药高等专科学校药学院,重庆 401331, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837548857308010, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, xref=2., ext=[AuthorCompanyExt(id=1329837548865696619, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, companyId=1329837548857308010, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.School of Pharmacy, Chongqing Medical and Pharmaceutical College, Chongqing 401331, China), AuthorCompanyExt(id=1329837548874085228, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, companyId=1329837548857308010, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.重庆医药高等专科学校药学院,重庆 401331)])])], keywords=[Keyword(id=1329837549553562487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, language=EN, orderNo=1, keyword=selective estrogen receptor degrader), Keyword(id=1329837549637448568, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, language=EN, orderNo=2, keyword=breast cancer), Keyword(id=1329837549721334649, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, language=EN, orderNo=3, keyword=elacestrant), Keyword(id=1329837549792637818, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, language=EN, orderNo=4, keyword=clinical efficacy), Keyword(id=1329837549863940987, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, language=EN, orderNo=5, keyword=safety), Keyword(id=1329837549926855548, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, language=CN, orderNo=1, keyword=选择性雌激素受体降解剂), Keyword(id=1329837549989770109, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, language=CN, orderNo=2, keyword=乳腺癌), Keyword(id=1329837550048490366, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, language=CN, orderNo=3, keyword=艾拉司群), Keyword(id=1329837550115599231, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, language=CN, orderNo=4, keyword=临床疗效), Keyword(id=1329837550182708096, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, language=CN, orderNo=5, keyword=安全性)], refs=[Reference(id=1329837550425977730, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Hwang KT, Kim J, Jung J, et al. Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database[J]. Clin Cancer Res, 2019, 25(6): 1970-1979., articleTitle=null, refAbstract=null), Reference(id=1329837550543418244, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Burstein HJ, Somerffeld MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update[J]. J Clin Oncol, 2021, 39(35): 3959-3977., articleTitle=null, refAbstract=null), Reference(id=1329837550665053062, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)[J]. Ann Oncol, 2020, 31(12): 1623-1649., articleTitle=null, refAbstract=null), Reference(id=1329837552233722760, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=McAndrew NP, Finn RS. Clinical review on the management of hormone receptor-positive metastatic breast cancer[J]. JCO Oncol Pract, 2022, 18(5): 319-327., articleTitle=null, refAbstract=null), Reference(id=1329837552317608841, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA. FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer[EB/OL]. (2023-01-27) [2023-06-06]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer., articleTitle=null, refAbstract=null), Reference(id=1329837552388912010, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Garner F, Shomali M, Paquin D, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models[J]. Anticancer Drugs, 2015, 26(9): 948-956., articleTitle=null, refAbstract=null), Reference(id=1329837552489575307, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Pancholi S, Simigdala N, Ribas R, et al. Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer[J]. NPJ Breast Cancer, 2022, 8(1): 125., articleTitle=null, refAbstract=null), Reference(id=1329837552560878477, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Bihani T, Patel HK, Arlt H, et al. Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER+ breast cancer patient-derived xenograft models[J]. Clin Cancer Res, 2017, 23(16): 4793-4804., articleTitle=null, refAbstract=null), Reference(id=1329837552758010766, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Shah MS, Kluetz PG. Multi-discipline review[EB/OL]. (2023-01-26) [2023-06-06]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217639Orig1s000MultidisciplineR.pdf., articleTitle=null, refAbstract=null), Reference(id=1329837552833508239, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Conlan MG, de Vries EFJ, Glaudemans A, et al. Pharmacokinetic and pharmacodynamic studies of elacestrant, a novel oral selective estrogen receptor degrader, in healthy post-menopausal women[J]. Eur J Drug Metab Pharmacokinet, 2020, 45(5): 675-689., articleTitle=null, refAbstract=null), Reference(id=1329837552946754448, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Bardia A, Aftimos P, Bihani T, et al. EMERALD: phase Ⅲ trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer[J]. Future Oncol, 2019, 15(28): 3209-3218., articleTitle=null, refAbstract=null), Reference(id=1329837553009669009, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Bardia A, Bidard FC, Neven P, et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting[J]. SABCS, 2022, 10: 6-10., articleTitle=null, refAbstract=null), Reference(id=1329837553093555090, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase Ⅲ EMERALD trial[J]. J Clin Oncol, 2022, 40(28): 3246-3256., articleTitle=null, refAbstract=null)], funds=[Fund(id=1329837550283371393, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, awardId=2022KYQD03, language=CN, fundingSource=2022年重庆城市管理职业学院高层次人才科研启动基金项目(2022KYQD03), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1329837548765033319, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, xref=1., ext=[AuthorCompanyExt(id=1329837548773421928, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, companyId=1329837548765033319, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of Smart Healthcare Industry, Chongqing City Management College, Chongqing 401331, China), AuthorCompanyExt(id=1329837548781810537, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, companyId=1329837548765033319, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.重庆城市管理职业学院智慧康养学院,重庆 401331)]), AuthorCompany(id=1329837548857308010, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, xref=2., ext=[AuthorCompanyExt(id=1329837548865696619, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, companyId=1329837548857308010, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.School of Pharmacy, Chongqing Medical and Pharmaceutical College, Chongqing 401331, China), AuthorCompanyExt(id=1329837548874085228, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, companyId=1329837548857308010, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.重庆医药高等专科学校药学院,重庆 401331)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.03.017, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.03.017, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2024.03.017, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2024.03.017, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1710000000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
口服选择性雌激素受体降解剂抗乳腺癌新药艾拉司群
曾凡新 1 , 王柯厶 2
世界临床药物 | 综述评论 2024,45(3): 338-340
收起
收藏切换
世界临床药物 |综述评论 2024 , 45 (3) : 338 -340
口服选择性雌激素受体降解剂抗乳腺癌新药艾拉司群
全屏
[Author(id=1329837548941194094, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329837549012497264, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, authorId=1329837548941194094, language=EN, stringName=Fanxin ZENG, firstName=Fanxin, middleName=null, lastName=ZENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.School of Smart Healthcare Industry, Chongqing City Management College, Chongqing 401331, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837549117354865, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, authorId=1329837548941194094, language=CN, stringName=曾凡新, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.重庆城市管理职业学院智慧康养学院,重庆 401331, bio={"content":"

曾凡新,教授,研究方向:新药研究开发。

"}, bioImg=null, bioContent=

曾凡新,教授,研究方向:新药研究开发。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837548765033319, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, xref=1., ext=[AuthorCompanyExt(id=1329837548773421928, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, companyId=1329837548765033319, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.School of Smart Healthcare Industry, Chongqing City Management College, Chongqing 401331, China), AuthorCompanyExt(id=1329837548781810537, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, companyId=1329837548765033319, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.重庆城市管理职业学院智慧康养学院,重庆 401331)])]), Author(id=1329837549205435251, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329837549335458677, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, authorId=1329837549205435251, language=EN, stringName=Kesi WANG, firstName=Kesi, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.School of Pharmacy, Chongqing Medical and Pharmaceutical College, Chongqing 401331, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837549402567542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, authorId=1329837549205435251, language=CN, stringName=王柯厶, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.重庆医药高等专科学校药学院,重庆 401331, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837548857308010, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, xref=2., ext=[AuthorCompanyExt(id=1329837548865696619, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, companyId=1329837548857308010, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.School of Pharmacy, Chongqing Medical and Pharmaceutical College, Chongqing 401331, China), AuthorCompanyExt(id=1329837548874085228, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837548194607972, companyId=1329837548857308010, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.重庆医药高等专科学校药学院,重庆 401331)])])]
曾凡新1, 王柯厶2
作者信息
  • 1.重庆城市管理职业学院智慧康养学院,重庆 401331
  • 2.重庆医药高等专科学校药学院,重庆 401331
作者简介:

曾凡新,教授,研究方向:新药研究开发。

Oral selective estrogen receptor depressant, the new anti-breast cancer drug elacestrant
Fanxin ZENG1, Kesi WANG2
Affiliations
  • 1.School of Smart Healthcare Industry, Chongqing City Management College, Chongqing 401331, China
  • 2.School of Pharmacy, Chongqing Medical and Pharmaceutical College, Chongqing 401331, China
出版时间: 2024-03-10 doi: 10.13683/j.wph.2024.03.017
文章导航
收藏切换

选择性雌激素受体降解剂(selective estrogen receptor degrader,SERD)是雌激素受体(estrogen receptor,ER)阳性的晚期乳腺癌(breast cancer)内分泌治疗的常用药物。艾拉司群(elacestrant)是治疗晚期乳腺癌ER阳性,人表皮细胞生长因子受体(human epidermal growth factor receptor,HER)2阴性的新型口服SERD,疗效优于其他内分泌治疗,可显著改善患者中位无进展生存期,且对于ER基因α突变的乳腺癌患者有效。艾拉司群的上市将为ER阳性、HER2阴性的晚期乳腺癌患者提供更有效的治疗药物选择。

选择性雌激素受体降解剂  /  乳腺癌  /  艾拉司群  /  临床疗效  /  安全性

Selective estrogen receptor degrader (SERD) is commonly used in the endocrine therapy of estrogen receptor (ER) positive advanced breast cancer. Elacestrant is a novel oral SERD that is for the treatment of advanced breast cancer with ER-positive and human epidermal growth factor receptor (HER)2-negative. It is more effective than other endocrine therapies and can significantly improve the median progression free survival of patients, and is also effective for breast cancer patients with ER gene α mutations. The launch of elacestrant will provide a more effective treatment option for patients with ER-positive, HER2-negative advanced breast cancer.

selective estrogen receptor degrader  /  breast cancer  /  elacestrant  /  clinical efficacy  /  safety
曾凡新, 王柯厶. 口服选择性雌激素受体降解剂抗乳腺癌新药艾拉司群. 世界临床药物, 2024 , 45 (3) : 338 -340 . DOI: 10.13683/j.wph.2024.03.017
Fanxin ZENG, Kesi WANG. Oral selective estrogen receptor depressant, the new anti-breast cancer drug elacestrant[J]. World Clinical Drug, 2024 , 45 (3) : 338 -340 . DOI: 10.13683/j.wph.2024.03.017
  • 2022年重庆城市管理职业学院高层次人才科研启动基金项目(2022KYQD03)
参考文献 引证文献
排序方式:
[1]
Hwang KT, Kim J, Jung J, et al. Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database[J]. Clin Cancer Res, 2019, 25(6): 1970-1979.
[2]
Burstein HJ, Somerffeld MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update[J]. J Clin Oncol, 2021, 39(35): 3959-3977.
[3]
Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)[J]. Ann Oncol, 2020, 31(12): 1623-1649.
[4]
McAndrew NP, Finn RS. Clinical review on the management of hormone receptor-positive metastatic breast cancer[J]. JCO Oncol Pract, 2022, 18(5): 319-327.
[5]
FDA. FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer[EB/OL]. (2023-01-27) [2023-06-06]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer.
[6]
Garner F, Shomali M, Paquin D, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models[J]. Anticancer Drugs, 2015, 26(9): 948-956.
[7]
Pancholi S, Simigdala N, Ribas R, et al. Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer[J]. NPJ Breast Cancer, 2022, 8(1): 125.
[8]
Bihani T, Patel HK, Arlt H, et al. Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER+ breast cancer patient-derived xenograft models[J]. Clin Cancer Res, 2017, 23(16): 4793-4804.
[9]
Shah MS, Kluetz PG. Multi-discipline review[EB/OL]. (2023-01-26) [2023-06-06]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217639Orig1s000MultidisciplineR.pdf.
[10]
Conlan MG, de Vries EFJ, Glaudemans A, et al. Pharmacokinetic and pharmacodynamic studies of elacestrant, a novel oral selective estrogen receptor degrader, in healthy post-menopausal women[J]. Eur J Drug Metab Pharmacokinet, 2020, 45(5): 675-689.
[11]
Bardia A, Aftimos P, Bihani T, et al. EMERALD: phase Ⅲ trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer[J]. Future Oncol, 2019, 15(28): 3209-3218.
[12]
Bardia A, Bidard FC, Neven P, et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting[J]. SABCS, 2022, 10: 6-10.
[13]
Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase Ⅲ EMERALD trial[J]. J Clin Oncol, 2022, 40(28): 3246-3256.
2024年第45卷第3期
16
2
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2024.03.017
  • 接收时间:2023-09-23
  • 首发时间:2026-11-18
  • 出版时间:2024-03-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2023-09-23
基金
2022年重庆城市管理职业学院高层次人才科研启动基金项目(2022KYQD03)
作者信息
    1.重庆城市管理职业学院智慧康养学院,重庆 401331
    2.重庆医药高等专科学校药学院,重庆 401331
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.03.017
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏